A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP)
Latest Information Update: 09 Dec 2021
At a glance
- Drugs Riociguat (Primary)
- Indications Idiopathic pulmonary fibrosis; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms RISE-IIP
- Sponsors Bayer
- 19 Feb 2021 Results of post-hoc analysis assessing impact of lung morphology on clinical outcomes published in the Journal of Heart and Lung Transplantation
- 14 Jan 2017 This trial has been completed in Portugal (End date:2016-09-14) as per European Clinical Trials Database record.
- 02 Oct 2016 This trial was completed in Spain.